Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artelo Biosciences ( (ARTL) ) has provided an update.
Artelo Biosciences, Inc. announced the completion of an underwritten offering of 640,924 shares of common stock and pre-funded warrants to purchase up to 40,894 shares, generating gross proceeds of approximately $3 million. The offering closed on September 5, 2025, and the underwriter partially exercised an over-allotment option on September 11, 2025, purchasing an additional 57,914 shares, resulting in gross proceeds of approximately $0.25 million.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 706,416
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.53M
Find detailed analytics on ARTL stock on TipRanks’ Stock Analysis page.